BECONASE AQ Nasal Spray is a metered-dose, manual pump spray unit containing a microcrystalline suspension of beclomethasone dipropionate, monohydrate equivalent to 42 mcg of beclomethasone dipropionate, calculated on the dried basis, in an aqueous medium containing microcrystalline cellulose, carboxymethylcellulose sodium, dextrose ...

FLIXONASE Aqueous Nasal Spray (0.05% w/w) is an aqueous suspension of microfine fluticasone propionate for topical administration to the nasal mucosa by means of a metering, atomising spray pump. Each 100 mg of spray delivered by the nasal adaptor contains 50 micrograms of fluticasone propionate.

Explore the list of the GSK products available for use, view prescribing information, and access detailed Healthcare Professional websites.

Below you can find a full list of our products. Our vaccines and medicines are approved in individual countries for specific uses and the information we provide is governed by local regulation. Patients should always ask a healthcare professional for advice.

FLIXONASE Aqueous Nasal Spray is indicated for the prophylaxis and treatment of seasonal allergic rhinitis including hay fever, and perennial rhinitis. In patients with allergic rhinitis, FLIXONASE Aqueous Nasal Spray is also indicated for …

AVAMYS (fluticasone furoate nasal spray) is indicated for the treatment of the symptoms of seasonal and perennial allergic rhinitis in patients 2 years of age and older.

Our leading research into conditions of type 2 inflammation mediated through the messenger molecule (cytokine) IL-5 has, and continues to, advance thinking about the most effective treatments for respiratory conditions like severe asthma, COPD and …

2021年2月9日 · BECONASE AQ Nasal Spray is indicated for the relief of the symptoms of seasonal or perennial allergic and nonallergic (vasomotor) rhinitis. Results from 2 clinical trials have shown that significant symptomatic relief was obtained within 3 days.

With over 50 years in respiratory care, GSK is committed to helping patients breathe better by continuously redefining treatment for COPD and asthma. We are driven by our commitment to research and uniting innovative science and technology to help people with these respiratory conditions live more comfortably.

This paper presents a comprehensive review of the scientific rationale of the current BE standard and their development history for nasal spray/aerosol products, as well as the Food and Drug Administration’s review and approval status of generic nasal sprays/aerosols with the application of these BE standard.